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Background: Increasing evidences have documented that microRNAs (miRNAs) act as oncogenes or tumor
suppressors in a variety types of cancer. The discovery of tumor associated miRNAs in serum of patients gives rise
to extensive investigation of circulating miRNAs in many human cancers which support the use of plasma/serum
miRNAs as noninvasive means of cancer detection. However, the aberrant expression of miRNAs and the circulating
miRNAs in bladder cancer are less reported.
Methods: We used Taqman probe stem-loop real-time PCR to accurately measure the levels of miR-99a in bladder
cancer cell lines, 100 pairs of bladder cancer tissues, the adjacent non-neoplastic tissues and plasma collected from
bladder cancer patients or control patients. miR-99a mimics were re-introduced into bladder cancer cells to
investigate its role on regulating cell proliferation which was measured by CCK-8 assay and cell cycle analysis.
Results: miR-99a was significantly down-regulated in bladder cancer tissues, and even the lower expression of
miR-99a was correlative with the more aggressive phenotypes of bladder cancer. Meanwhile, enforced expression
of miR-99a can inhibit the cell proliferation of bladder cancer cells. Furthermore, investigation of the expression of
miR-99a in plasma of bladder cancer patients showed that miR-99a was also decreased in plasma of bladder cancer
patients. The results strongly supported miR-99a as the potential diagnostic marker of bladder cancer.
Conclusions: Our data indicated that miR-99a might act as a tumor suppressor in bladder cancer and was significantly
down-regulated in development of bladder cancer.
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Bladder cancer is one of the most frequent malignancies
in the world. The most common type of bladder cancer
is urothelial carcinoma of the bladder. Chromosomal
anomalies, genetic polymorphisms, genetic and epigenetic
alterations have been reported to be included in the
tumorigenesis and progression of bladder cancer [1]. Many
molecules involved in these alterations may serve as diag-
nostic markers of tumor growth and disease progression.
Currently, many protein-coding genes and specific gen-
omic regions are the most popular used molecular markers
of bladder cancer, such as members of the RAS family, dif-
ferentially methylated DNA locus [2-4].
MicroRNAs (miRNAs) are endogenous small non-coding
RNAs that play crucial roles in multiple biological processes* Correspondence: Kangyongming1979@163.com
Department of Urology, Suining Central Hospital, 127 Deshengxi Road,
Suining, Chuanshan District 629000, P.R. China
© 2014 Feng et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.through regulating mRNAs for cleavage or translational
repression. Recent studies have documented that miRNAs
acted as oncogenes or tumor suppressors in a variety types
of cancer, such as lung, breast, hepatic, and pancreatic
cancer [5-10]. Several innate properties of miRNAs make
them attractive as potential biomarkers. MiRNAs can be
detected easily in small amount samples using specific
and sensitive quantitative real-time PCR; miRNAs are
stable against degradation and can be detectable in bodily
fluids including serum, plasma, saliva, urine and tears
[11,12]. Furthermore, expression profiles of miRNAs would
be changed in the plasma and/or serum of cancer patients
and miRNAs have been shown to be released from tumor
cells to the circulation [13]. So circulating miRNAs will be
a novel class of non-invasive biomarkers for cancer diag-
nosis and prognosis. However, the expression profile of
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compared with the abroad reports in other cancer types.
miR-99a was proved to be down-regulated in bladder
cancer patients by deep sequencing in nine bladder urothelial
carcinoma patients [14], low-grade bladder cancer patients
[15] and was also reported to act as a tumor suppressor in
several other cancer types. For example, miR-99a could
promote apoptosis by targeting mTOR in human esopha-
geal squamous cell carcinoma [16]. In addition, miR-99a
induces G1-phase cell cycle arrest and suppresses tumori-
genicity in renal cell carcinoma [17]. Down-regulation of
miR-99a in oral squamous cell carcinomas also contrib-
utes to the growth and survival of oral cancer cells [18].
However, the expression pattern of miR-99a in large num-
bers of bladder cancer patients and its roles in bladder
cancer are unknown.
In this study, we used Taqman probe stem-loop real-
time PCR to accurately measure the levels of miR-99a in
100 pairs of bladder cancer tissues and the adjacent non-
neoplastic tissues to exclude the differences of miR-99a ex-
pression in different individuals. We found that miR-99a
was significantly down-regulated in bladder cancer tissues
and enforced expression of miR-99a repressed the prolif-
eration of bladder cancer cells. Furthermore, investigation
of the expression of miR-99a in the plasma of bladder can-
cer patients showed that miR-99a was also decreased in
plasma of bladder cancer patients which strongly sup-
ported miR-99a as the potential diagnostic marker of
bladder cancer.
Methods
Cell culture and transfections
The human bladder cancer cell lines (J82, HT1376, RT4,
T24 and TCCSUP) and immortalized human bladder
epithelium (HCV29 and HU609) cells were propagated
in DMEM (Invitrogen) supplemented with 10% FCS at
37°C in 5% CO2 cell culture incubator. miR-99a mimics
and scramble control mimics were obtained from Dharmacon
(Austin, TX, USA) and transfected with DharmFECT1
(Dharmacon, Austin, TX, USA) in HT1376 and J82 cells
at a final concentration of 50 nM.
Patients and specimens
The human clinical samples were collected from surgical
specimens from 100 patients with bladder cancer at
Suining Central Hospital. The corresponding adjacent
non-neoplastic tissues from the macroscopic tumor
margin were isolated at the same time and used as controls.
All samples were immediately snapped frozen in liquid
nitrogen and stored at −80°C until RNA extraction.
Whole blood samples were prospectively collected
from bladder cancer patients and control patients without
urologic malignancies. Whole blood (5–8 ml) was col-
lected in an ethylene diamine tetracetic acid (EDTA) tube.The sample was centrifuged twice at 4°C. Plasma
(supernatant after second centrifugation) was then
stored at −80°C. The Clinical Research Ethics Committee
of Suining Central Hospital approved the research proto-
cols and written informed consent was obtained from the
participants.
RNA extraction, cDNA synthesis, and real-time PCR assays
Total RNA was extracted from tissues and cells using
Trizol reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. Total RNA of plasma was
isolated using a commercially available kit (mirVana;
miRNA Isolation Kit, Applied Biosystems, Carlsbad, CA)
according to the manufacturer’s protocol. RNA was quan-
tified and cDNA was synthesized by M-MLV reverse tran-
scriptase (Invitrogen) from 2 μg of total RNA. A stem-loop
RT primer was used for the reverse transcription. Quanti-
tative RT-PCR was performed in a Bio-Rad CFX96 real-
time PCR System (Bio-Rad, CA, USA) using TaqMan
probes (Applied Biosystems, Foster City, CA, USA) ac-
cording to the manufacturer’ s instructions. The PCR
conditions were as follows: 95°C for 30 s, followed by
40 cycles of 95°C for 5 s and 60°C for 34 s. The data
were normalized using the endogenous U6 snRNA. The
2-ΔΔCT method was used in the analysis of PCR data.
Primer sequences are presented in Table 1.
Cell proliferation assay
To measure the effect of miRNA mimics on cell prolifer-
ation, cells were incubated in 10% CCK-8 (DOJINDO)
diluted in culture media at 37°C until visual color con-
version appeared. Proliferation rates were determined
at 12, 24, 48, 72, 96 h post-transfection, and quantification
was done on a microtiter plate reader (Spectra Rainbow,
Tecan) according to the manufacturer’s protocol.
Cell cycle analysis
HT1376 and J82 cells were harvested and washed once
at 4°C in PBS containing 0.5% BSA then added ice cold
70% ethanol. The fixed cells were immediately stored
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in ice cold PBS to remove ethanol and then resuspended
in PBS with 25 μg/ml RNase A and 50 μg/ml Propidium
Iodide at 37°C for 1 hour. Flow cytometry was performed
using a Beckman Coulter and analyzed with ModFit.
Statistics
The statistical analyses for miR-99a expression in clinical
samples, correlation of miR-99a expression with patients’
clinicopathological variables were conducted using the
Bonferroni multiple-comparison test. The other statis-
tical analyses were evaluated by Independent samples
T test (two-tailed). P ≤ 0.05 was considered statistically
significant.
Results
miR-99a is down-regulated in bladder cancer cells
To analyze the expression of miR-99a in bladder cancer,
q-PCR using Taqman probes was conducted to measure
the levels of miR-99a. We firstly examined the expres-
sion of mature miR-99a in five human bladder cancerFigure 1 miR-99a is significantly down-regulated in bladder cancer ce
miR-99a in two immortalized human bladder epithelium cells (HCV29 and
TCCSUP). Data are shown as mean ± s.d. (n = 3); **indicates P-value < 0.01; *
(C) tissue and adjacent non-neoplastic tissues (N) of 2 patients with bladder c
(C) and adjacent non-neoplastic tissues (N). (D) Normalized expression of miR-cell lines (J82, HT1376, RT4, T24 and TCCSUP) and
immortalized human bladder epithelium (HCV29 and
HU609) cells. The expression level of miR-99a in HU609
and HCV29 was significantly higher than that in the three
bladder cancer cell lines (T24, HT1376, and J82) and
was non-significantly but observably higher than the
levels in the other two bladder cancer cell lines (TCCSUP
and RT4) (Figure 1A). These data demonstrated that the
down-regulation of miR-99a might be relevant to the gen-
esis and development of bladder cancer.
miR-99a is down-regulated in bladder cancer tissues
compared with the corresponding adjacent
non- neoplastic tissues
To further analyze the expression of miR-99a in patients
with bladder cancer, we measured the levels of miR-99a
in 100 pairs of bladder cancer tissues (C) and the adjacent
non-neoplastic tissues (N). Figure 1B showed the represen-
tative HE staining of the bladder cancer (C) tissue and ad-
jacent non-neoplastic tissues (N) of 2 patients with bladder
cancer. The results of PCR showed that 53/100 (53%) ofll lines and in bladder cancer tissues. (A) The expression level of
HU609) and five bladder cancer cell lines (J82, HT1376, RT4, T24 and
**indicates P-value < 0.001. (B) HE staining of the bladder cancer
ancer. (C) The relative expression of miR-99a in 100 pairs of bladder cancer
99a in 100 pairs of bladder cancer and adjacent normal tissues.
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sues compared with the corresponding non-neoplastic tis-
sues when the cutoff was set up as 1.5 (Figure 1C). There
were 20/100 (20%) of cases which had increased levels
of miR-99a in bladder cancer tissues compared with the
adjacent non-neoplastic tissues, 27/100 (27%) of cases
in whom the expression of miR-99a was unchanged in
bladder cancer tissues when the cutoff was set up as 1.5.
The results also showed that the average expression of
miR-99a in bladder cancer samples was significantly
lower than that in the adjacent non-neoplastic tissues
(p < 0.001) (Figure 1D). Collectively, the data indicated
that miR-99a was significantly attenuated in tumor tis-
sues compared with adjacent normal tissues and might
act as a tumor suppressor in bladder cancer.
Low-level expression of miR-99a is associated with
aggressive phenotypes of bladder cancer
To further investigate the correlation between the expres-
sion of miR-99a and the clinicopathological characteristics,
the relative expression of miR-99a in 100 pairs of bladder
cancer tissues and adjacent normal tissues was statistically
analyzed. The clinicopathological features of bladder can-
cer patients were summarized in Table 2. Correlation ana-
lysis showed that low-level expression of miR-99a in
bladder cancer was significantly associated with a more ex-
tensive muscle invasion (p < 0.05, stage Ta, 1 vs. stage T2,
3, 4) (Figure 2A) and a more aggressive tumor phenotype
(p < 0.05, grade 1, 2 vs. grade 3) (Figure 2B). The data also
demonstrated that the expression level of miR-99a had no
correlation with age, gender and histological type. The cor-
relation of lower levels of miR-99a with the more aggres-
sive phenotype of bladder cancer strongly indicated that
miR-99a played important roles in bladder carcinogenesis
as a tumor suppressor.
Enforced expression of miR-99a suppresses bladder
cancer cell growth
To explore the role of miR-99a in bladder carcinogenesis,
we overexpressed miR-99a in the two bladder cancer cell
lines HT1376 and J82 in which expression of miR-99a was
lower than the other bladder cancer cell lines. Successful
overexpression of miR-99a upon transfection in the two
bladder cancer cell lines was confirmed by q-PCR. As
shown in Figure 3A and 3D, miR-99a was overexpressed
about 20 folds and 18 folds than the scramble control or
untreated cells in HT1376 and J82 cells respectively. As
demonstrated by CCK-8 growth assays at 0, 12, 24, 48, 72,
96 hours after mimic transfection, overexpression of miR-
99a reduced cell proliferation in both the two cell lines,
whereas the scramble control had no effect on cell prolif-
eration compared with the untreated cells (Figure 3B, E).
The suppression of miR-99a on cell proliferation of
HT1376 cells was a little stronger than that on J82 cells.The results improved that miR-99a acted as a tumor sup-
pressor in bladder cancer and the down-regulation of
miR-99a in bladder tissues would lead to the unlimited cell
proliferation. We also checked the cell cycle distribution in
HT1376 and J82 cells transfected with miR-99a mimics. The
results showed that miR-99a could increase the fraction of
cells in G1 phases in HT1376 and J82 cells which suggested
that miR-99a might inhibit bladder cancer cell growth
through arresting the G1/S transition (Figure 3C, 3F).
miR-99a is also down-regulated in the plasma of patients
with bladder cancer
To explore the diagnostic potential of miR-99a in bladder
cancer, we detected the expression of miR-99a in the
Figure 2 Correlation of the relative expression of miR-99a with the clinicopathological characteristics of patients with bladder cancer.
(A) The correlation of miR-99a expression with tumor stages of bladder cancer tissues. (B) The correlation of miR-99a expression with tumor
grades of bladder cancer tissues.
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individuals. The data demonstrated that the average level
of miR-99a in the bladder cancer patients was significantly
lower than that in the healthy individuals (Figure 4A). The
expression profile of miR-99a in the plasma was consistent
with its down-regulation in bladder cancer tissues. TheFigure 3 Enforced expression of miR-99a inhibits cell proliferation of
was confirmed by qRT-PCR. (B) The cell growth of HT1376 at 0, 12, 24, 48,
(C) Cell cycle distribution of HT1376 cells transfected with miR-99a mimics.
(E) The cell growth of J82 at 0, 12, 24, 48, 72, 96 hours post transfection wh
transfected with miR-99a mimics. Data are shown as mean ± s.d. (n = 3); **iresults suggested that miR-99a could be released from the
bladder epithelium to blood and down-regulation of miR-
99a in plasma might origin from decreased expression of
miR-99a in cancer tissues. The low-level expression of
miR-99a in the plasma of bladder cancer patients was also
significantly associated with a more aggressive tumorbladder cancer cells. (A) Overexpression of miR-99a in HT1376 cells
72, 96 hours post transfection which was detected by CCK-8 assay.
(D) Overexpression of miR-99a in J82 cells was confirmed by qRT-PCR.
ich was detected by CCK-8 assay. (F) Cell cycle distribution of J82 cells
ndicates P-value < 0.01; ***indicates P-value < 0.001.
Figure 4 Expression of miR-99a in the plasma of patients with bladder cancer. (A) Normalized expression of miR-99a in the plasma of
50 patients with bladder cancer and 50 healthy individuals. (B) Correlation of miR-99a expression in the plasma with the tumor grades of
bladder cancer.
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decreased expression of miR-99a in the plasma of bladder
cancer patients suggested that miR-99a could be devel-
oped to a potential diagnostic marker which can be com-
bined with other miRNAs’ expression to detect bladder
cancer.
Discussion
The aberrant expression of miRNAs in bladder cancer
has been studied in recent years. Some miRNAs have
been reported to be up-regulated in bladder cancer tis-
sues. For example, miR-129 was the most commonly up-
regulated and its up-regulation was associated with poor
outcome [19]; the expression of miR-96 and miR-183 in
urine was significantly correlated with tumor stage and
grade, and their expressions were significantly decreased
after radical surgery [20]; miR-133b and miR-518c were
also strongly up-regulated in bladder cancer tissues [19].
Meanwhile, some miRNAs were reported to be down-
regulated in cancer tissues and might function as tumor
suppressors. miR-200 family members were lower in
urine sediment of bladder cancer patients and increased
significantly following surgery which suggested this
microRNA family could be used as diagnostic and prog-
nostic markers of bladder cancer [21]. miR-92 and miR-
33 were reported to be down-regulated in the plasma of
patients with bladder cancer and the expression of these
two miRNAs was inversely correlated with the clinical
stage of the cancer [22]. Because miRNAs are small, easy
to deliver, stable against degradation and easy to be de-
tected, these aberrant expression miRNAs in bladder
cancer are attractive as potential biomarkers and new
targets for bladder cancer therapy. However, the poten-
tial diagnostic and therapeutic roles of these miRNAs in
great numbers of clinical samples are just at the begin-
ning and need to be explored further.
Among the miRNAs which were aberrantly expressed
in bladder cancer, miR-99a was reported to be down-regulated in bladder cancer patients by deep sequencing
in nine bladder urothelial carcinoma patients [14]. Catto
et al. also reported the expression of miR-99a was down-
regulated in low-grade bladder cancer patients and also
identified a target of miR-99a in bladder cancer progres-
sion [15]. Different to these reports, we investigated
miR-99a expression in tumor tissues and the adjacent
non-neoplastic tissues which were derived from a com-
mon patient instead of different individuals to exclude
the differences of miR-99a expression in different indi-
viduals. In addition, we detected miR-99a expression in
more clinical samples and also in the plasma of bladder
cancer patients. Our investigation of miR-99a levels in
100 pairs of bladder cancer tissues and adjacent normal
tissues showed that miR-99a was authentically decreased
in bladder cancer tissues. Moreover, the lower level of
miR-99a was correlative with more aggressive phenotype
of bladder cancer. Reintroduction of miR-99a into the
bladder cancer cells which had lower expression of miR-
99a could inhibit the unlimited cell proliferation. Col-
lectively, the data indicated that miR-99a functioned as a
tumor suppressor in bladder cancer. The roles of miR-
99a in regulating bladder cancer cell migration, invasion
and apoptosis and the detailed mechanism will be our
further directions.
Earlier studies discovered that extracellular miRNAs
circulated in the bloodstream and the circulating miR-
NAs were remarkably stable. Detection of elevated levels
of tumor associated miRNAs in serum of patients with
diffuse large B-cell lymphoma [23] leads to wide investi-
gation of circulating miRNAs in many human cancers,
including breast cancer [24], lung cancer [25], prostate
cancer [26], and renal cell carcinoma [27] and so on.
The expression profile of miRNAs in serum/plasma of
the patients with bladder cancer was also investigated
and some important circulating miRNAs in bladder can-
cer had been identified [28,29]. These studies support
the use of serum/plasma miRNAs as noninvasive means
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ports about miRNAs down-regulated in the plasma of
patients with bladder cancer relative to the extensive
studies of miRNAs up-regulated in plasma. We found
that the levels of miR-99a in the plasma of bladder can-
cer was decreased which was consistent with its low
level in the cancer tissues although it was unknown how
the down-regulation of miR-99a in a relatively small
number of tumor cells can affect the plasma miR-99a
levels. We think there are two possible explanations for
that: 1) The down-regulation of miR-99a in the cancer
tissue was significant enough to be able to affect plasma
miR-99a levels, meanwhile, the Taqman probe stem-loop
real-time PCR was sensitive enough to detect the faint
change of miR-99a levels in plasma. 2) The down-
regulation of miR-99a in the plasma not only origin from
the tumor cells but also from the immunocytes in the
tumor microenvironment which needs to be improved
further. The decreased expression of miR-99a in the
plasma and cancer tissues of bladder cancer patients
supported that miR-99a can be developed as a new diag-
nostic marker for bladder cancer detection.
Conclusion
In summary, we determined the low expression of miR-99a
in the cancer tissues and plasma of patients with blad-
der cancer and also indicated the tumor suppressor role
of miR-99a in bladder cancer. Our data provided the
potential diagnostic and therapeutic roles of miR-99a in
bladder cancer.
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